Heart failure & cardiomyopathiesCohort study

Cost Offset With Quadruple Therapy for Heart Failure

JAMA CardiolPublished

  • Economic evaluation
  • registry-based
  • Medicare-linked
  • modelled treatment effects from pivotal randomized clinical trials (RCTs)

Authors' conclusion

Among US adults hospitalized with HFrEF, 1-year health care costs are substantial and driven predominantly by hospitalizations. Using combined trial effects and real-world Medicare data, this study found that implementation of quadruple GDMT would meaningfully reduce hospitalization-associated costs and often yield net savings after accounting for medication expenses.

Study context

Population
Adults ≥65 years hospitalized with heart failure with reduced ejection fraction (HFrEF), Get With The Guidelines-Heart Failure (GWTG-HF) registry linked to Medicare, 2016–2020
Participants
50,598 adults
Exposure
Full quadruple guideline-directed medical therapy (GDMT) vs partial GDMT
Outcome
Mean per-patient total health care costs (Medicare Parts A and B) and net annual cost
Follow-up
1 year after discharge

Main finding

As reported in the abstract

Hospitalization-associated expenditures and net annual cost · 1 year

Reduction in hospitalization-associated expenditures

$9780 per patient annually

95% CI $7900-$11 660

Mean 1-year total health care costs per patient
$41 802
Costs attributable to all-cause hospitalizations per patient
$25 172
Annual drug costs
$1223 to $16 136
Net annual cost (most regimens yielding net savings)
$8556 in savings to $6347 in net cost

Observational data: associations, not effects.

Further findings

OutcomeEstimate
HF hospitalizations · modelledrelative reduction 87% (95% CI 81%–91%)
All-cause hospitalizations · modelledreduction 61% (95% CI 51%–68%)

Original publication

Cost Offset With Quadruple Therapy for Heart Failure. JAMA Cardiol. Published 1 August 2026. doi:10.1001/jamacardio.2026.1552

Summarised from the published abstract; every number is checked against it